Trial Profile
A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ontorpacept (Primary) ; Atezolizumab; Avelumab; Durvalumab; Nivolumab; Peginterferon alfa-2a; Pembrolizumab; Talimogene laherparepvec
- Indications Cutaneous T-cell lymphoma; Malignant melanoma; Multiple myeloma; Mycosis fungoides; Plasmacytoma; Sezary syndrome; Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 28 Apr 2021 According to a Trillium Therapeutics media release, updated data from this study will be presented at medical conference in 4Q 2021.
- 13 May 2020 Status changed from recruiting to discontinued.
- 08 Feb 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.